117 related articles for article (PubMed ID: 3497093)
1. Variant sublines of the human B-lymphoma cells Namalwa are at different stages of differentiation.
Guy K; Middleton PG; Steel CM
Immunology; 1987 Jul; 61(3):383-6. PubMed ID: 3497093
[TBL] [Abstract][Full Text] [Related]
2. MHC class II antigen and immunoglobulin expression in spontaneous phenotypic variants of the Burkitt's lymphoma cell line Namalwa.
Guy K; Middleton PG; Docherty LJ; De Angelis CL; Steel CM
Immunology; 1986 Dec; 59(4):603-10. PubMed ID: 3026962
[TBL] [Abstract][Full Text] [Related]
3. Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.
Sieverts H; Alabaster O; Goldschmidts W; Magrath I
Cancer Res; 1986 Mar; 46(3):1182-8. PubMed ID: 3080238
[TBL] [Abstract][Full Text] [Related]
4. Cluster differentiation antigen expression, proliferative activity and clinical stage in centroblastic centrocytic lymphomas.
Williamson JM; Grigor I; Smith ME; Holgate CS; Quirke P; Bird CC; Alison DL; Child JA
J Pathol; 1986 Sep; 150(1):51-9. PubMed ID: 3491205
[TBL] [Abstract][Full Text] [Related]
5. Recurrent mutation of immunoglobulin and c-myc genes and differential expression of cell surface antigens occur in variant cell lines derived from a Burkitt lymphoma.
Guy K; Middleton PG; Bansal NS; Ross JA; Steel CM
Int J Cancer; 1990 Jan; 45(1):109-18. PubMed ID: 2298494
[TBL] [Abstract][Full Text] [Related]
6. [Establishment and characterization of an interleukin-2 receptor bearing a Burkitt's lymphoma cell line (ABL-2)].
Matsuo Y; Motoori T; Irie K; Natori H; Hayashi A; Mizote H; Sagawa K; Yokoyama MM
Nihon Ketsueki Gakkai Zasshi; 1985 Aug; 48(5):1187-97. PubMed ID: 3934897
[No Abstract] [Full Text] [Related]
7. B cell growth and differentiation induced by supernatants of transformed epithelial cell lines.
Rawle FC; Shields J; Smith SH; Iliescu V; Merkenschlager M; Beverley PC; Callard RE
Eur J Immunol; 1986 Aug; 16(8):1017-9. PubMed ID: 3091374
[TBL] [Abstract][Full Text] [Related]
8. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.
Hirano T; Yasukawa K; Harada H; Taga T; Watanabe Y; Matsuda T; Kashiwamura S; Nakajima K; Koyama K; Iwamatsu A
Nature; 1986 Nov 6-12; 324(6092):73-6. PubMed ID: 3491322
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a human B-cell tumor in athymic mice.
Leonard JE; Johnson DE; Felsen RB; Tanney LE; Royston I; Dillman RO
Cancer Res; 1987 Jun; 47(11):2899-902. PubMed ID: 3105870
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of B cell growth and differentiation factors.
Mayer L; Kunkel HG
Lymphokine Res; 1984; 3(3):107-11. PubMed ID: 6611466
[No Abstract] [Full Text] [Related]
11. Kinetics of Ii synthesis, processing, and turnover in n-butyrate-treated Burkitt's lymphoma cell lines which express or do not express class II antigens and in hairy leukemic cells.
Spiro RC; Sairenji T; Humphreys RE
J Immunol; 1985 May; 134(5):3539-49. PubMed ID: 3856614
[TBL] [Abstract][Full Text] [Related]
12. The A-myb gene is preferentially expressed in tonsillar CD38+, CD39-, and sIgM- B lymphocytes and in Burkitt's lymphoma cell lines.
Golay J; Erba E; Bernasconi S; Peri G; Introna M
J Immunol; 1994 Jul; 153(2):543-53. PubMed ID: 8021494
[TBL] [Abstract][Full Text] [Related]
13. Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin.
Favrot MC; Philip I; Philip T; Portoukalian J; Doré JF; Lenoir GM
J Natl Cancer Inst; 1984 Oct; 73(4):841-7. PubMed ID: 6592381
[TBL] [Abstract][Full Text] [Related]
14. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
Klein G; Ehlin-Henriksson B; Schlossman SF
J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
[TBL] [Abstract][Full Text] [Related]
15. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides.
Henault M; Lee LN; Evans GF; Zuckerman SH
J Immunol Methods; 2005 May; 300(1-2):93-9. PubMed ID: 15894327
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of a human B cell hybridoma with interleukin-2 receptor.
Ikewaki N
Kitasato Arch Exp Med; 1990 Apr; 63(1):31-6. PubMed ID: 2273757
[TBL] [Abstract][Full Text] [Related]
17. Regulation of class II gene expression in a murine pre-B cell line.
Polla BS; Poljak A; Geier S; Nathenson SG; Ohara J; Paul WE; Glimcher LH
Fed Proc; 1986 Dec; 45(13):2995-9. PubMed ID: 3536599
[TBL] [Abstract][Full Text] [Related]
18. [Studies of the mechanisms of human B cell activation. III. Development of an assay system for human B cell differentiation factors (BCDF) and identification of BCDF-producing T cell subsets].
Suzuki N; Sakane T; Ueda Y; Takada S; Murakawa Y; Tsunematsu T; Tsuchiya T; Niwa Y
Arerugi; 1984 Nov; 33(11):963-9. PubMed ID: 6335652
[No Abstract] [Full Text] [Related]
19. Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Ho YS; Subhendu C; Hsu SM
Cancer Invest; 1987; 5(2):101-7. PubMed ID: 2955857
[TBL] [Abstract][Full Text] [Related]
20. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
Jox A; Taquia E; Vockerodt M; Draube A; Pawlita M; Möller P; Bullerdiek J; Diehl V; Wolf J
Cancer Res; 1998 Nov; 58(21):4930-9. PubMed ID: 9810002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
